Skip to Content

New Drug Approvals Archive - July 2014

July 2014

Beleodaq (belinostat) Injection

Date of Approval: July 3, 2014
Company: Spectrum Pharmaceuticals, Inc.
Treatment for: Peripheral T-cell Lymphoma

Beleodaq (belinostat) is a histone deacetylase (HDAC) inhibitor for the treatment of peripheral T-cell lymphoma (PTCL).

Kerydin (tavaborole) Topical Solution

Date of Approval: July 7, 2014
Company: Anacor Pharmaceuticals
Treatment for: Onychomycosis -- Toenail

Kerydin (tavaborole) is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails.

Rasuvo (methotrexate) Injection - formerly MPI-2505

Date of Approval: July 11, 2014
Company: Medac Pharma, Inc.
Treatment for: Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Psoriasis

Rasuvo (methotrexate) is a subcutaneous, ready-to-use autopen formulation of methotrexate for the treatment of rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis.

Ruconest (C1 esterase inhibitor (recombinant)) - formerly Rhucin

Date of Approval: July 16, 2014
Company: Pharming Group NV
Treatment for: Hereditary Angioedema

Ruconest is a C1 esterase inhibitor [recombinant] indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).

Zydelig (idelalisib) Tablets

Date of Approval: July 23, 2014
Company: Gilead Sciences, Inc.
Treatment for: non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma

Zydelig (idelalisib) is a phosphoinositide 3-kinase (PI3K) delta inhibitor for the treatment of chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma.

Targiniq ER (naloxone and oxycodone) Extended-Release Tablets

Date of Approval: July 23, 2014
Company: Purdue Pharma L.P.
Treatment for: Pain

Targiniq ER (naloxone and oxycodone) is an opioid antagonist and opioid analgesic combination in a long-acting abuse-deterrent formulation for the management of chronic severe pain.

Ryanodex (dantrolene) Injectable Suspension

Date of Approval: July 22, 2014
Company: Eagle Pharmaceuticals, Inc.
Treatment for: Malignant Hyperthermia

Ryanodex (dantrolene) is a skeletal muscle relaxant in a concentrated formulation for the treatment of malignant hyperthermia.

Flonase Allergy Relief (fluticasone propionate) Nasal Spray

Date of Approval: July 23, 2014
Company: GlaxoSmithKline plc
Treatment for: Allergic Rhinitis

Flonase Allergy Relief (fluticasone propionate) is a once-a-day, over-the-counter corticosteroid nasal spray indicated for the relief hay fever symptoms.

Acticlate (doxycycline hyclate) Tablets

Date of Approval: July 25, 2014
Company: Aqua Pharmaceuticals, LLC
Treatment for: Bacterial Infection, Acne

Acticlate (doxycycline hyclate) is a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne.

Imbruvica (ibrutinib)

New Indication Approved: July 28, 2014
Treatment for: Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia; Waldenström’s Macroglobulinemia; Small Lymphocytic Lymphoma; Marginal Zone Lymphoma; Chronic Graft Versus Host Disease

Eylea (aflibercept)

New Indication Approved: July 29, 2014
Treatment for: Macular Degeneration; Macular Edema; Diabetic Retinopathy; Diabetic Macular Edema

Striverdi Respimat (olodaterol) Inhalation Spray

Date of Approval: July 31, 2014
Company: Boehringer Ingelheim Pharmaceuticals Inc.
Treatment for: Chronic Obstructive Pulmonary Disease

Striverdi Respimat (olodaterol) is a once-daily, long-acting beta-agonist (LABA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.